Pro-Regenerative Signaling after Acetaminophen-Induced Acute Liver Injury in Mice Identified Using a Novel Incremental Dose Model  by Bhushan, Bharat et al.
The American Journal of Pathology, Vol. 184, No. 11, November 2014GASTROINTESTINAL, HEPATOBILIARY, AND PANCREATIC PATHOLOGY
Pro-Regenerative Signaling after Acetaminophen-Induced
Acute Liver Injury in Mice Identiﬁed Using a Novel
Incremental Dose Model
Bharat Bhushan,* Chad Walesky,* Michael Manley,* Tara Gallagher,* Prachi Borude,* Genea Edwards,*
Satdarshan P.S. Monga,y and Udayan Apte*
ajp.amjpathol.orgFrom the Department of Pharmacology, Toxicology, and Therapeutics,* University of Kansas Medical Center, Kansas City, Kansas; and the Department of
Pathology and Medicine,y University of Pittsburgh School of Medicine, Pittsburgh, PennsylvaniaAccepted for publicationC
P
hJuly 15, 2014.
Address correspondence to
Udayan Apte, Ph.D.,
Department of Pharmacology,
Toxicology and Therapeutics,
University of Kansas Medical
Center, 3901 Rainbow Blvd,
MS1018, Kansas City,
KS 66160. E-mail: uapte@
kumc.edu.opyright ª 2014 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2014.07.019Acetaminophen (APAP) overdose results in acute liver failure and has limited treatment options. Previous
studies show that stimulating liver regeneration is critical for survival after APAP overdose, but the
mechanisms remain unclear. In this study, we identiﬁed major signaling pathways involved in liver
regeneration after APAP-induced acute liver injury using a novel incremental dose model. Liver injury and
regeneration were studied in C57BL/6 mice treated with either 300 mg/kg (APAP300) or 600 mg/kg
(APAP600) APAP. Mice treated with APAP300 developed extensive liver injury and robust liver regen-
eration. In contrast, APAP600-treated mice exhibited signiﬁcant liver injury but substantial inhibition of
liver regeneration, resulting in sustained injury and decreased survival. The inhibition of liver regener-
ation in the APAP600 group was associated with cell cycle arrest and decreased cyclin D1 expression.
Several known regenerative pathways, including the IL-6/STAT-3 and epidermal growth factor receptor/
c-Met/mitogen-activated protein kinase pathways, were activated, even at APAP600, where regeneration
was inhibited. However, canonical Wnt/b-catenin and NF-kB pathways were activated only in
APAP300-treated mice, where liver regeneration was stimulated. Furthermore, overexpression of a stable
form of b-catenin, where serine 45 is mutated to aspartic acid, in mice resulted in improved liver
regeneration after APAP overdose. Taken together, our incremental dose model has identiﬁed a differ-
ential role of several signaling pathways in liver regeneration after APAP overdose and highlighted
canonical Wnt signaling as a potential target for regenerative therapies for APAP-induced acute liver
failure. (Am J Pathol 2014, 184: 3013e3025; http://dx.doi.org/10.1016/j.ajpath.2014.07.019)Supported by NIH grants P20 RR021940, 5T32ES007079-34, and
1R01DK098414, an American Association for the Study of Liver Diseases/
American Liver Foundation Liver Scholar Award, and grant 1R01DK098414.
Disclosures: None declared.Acetaminophen (APAP) is one of the most widely used over-
the-counter analgesic and antipyretic drugs in the world.
APAP is safe at therapeutic doses, but overdose can cause
acute liver failure (ALF). In fact, APAP overdose is associ-
ated with 56,000 emergency department visits and 26,000
hospitalizations every year in the United States.1 The only
pharmacological intervention, at present, is N-acetyl cysteine
(precursor of glutathione), which is successful only if given
within a few hours after APAP overdose.2 An ultimate option
is liver transplantation, which is complicated by issues such
as donor availability, long-term immunosuppression, and
exorbitant costs.3
Previous studies suggest that liver regeneration after
APAP overdose plays a critical role in determination ofstigative Pathology.
.outcome of injury.4e7 a-Feto protein, a marker of liver
regeneration, was found to be associated with better survival
rate in patients with APAP-induced ALF.4 Several other
studies in animal models suggest that timely stimulation of
liver regeneration, such as with stem cell factor6 and vascular
endothelial growth factor,7 improves survival after APAP
overdose in mice. These studies highlight stimulating liver
regeneration in APAP-induced patients with ALF as a
plausible therapeutic option. However, the mechanisms of
Bhushan et alliver regeneration after APAP-induced ALF are not well
known. Although liver regeneration has been extensively
studied in the past,8 most of the studies are on the basis of a
partial hepatectomy (PHX) model, a mechanistically
different model from APAP-induced ALF.
Data on hepatotoxicants, in general, suggest that liver
regeneration follows the principles of dose-response.9 Studies
indicate that liver regeneration after toxic injury to liver in-
creases proportionately to injury but only up to a threshold
dose. Doses higher than the threshold dose actually inhibit
liver regeneration, resulting in progression of injury to ALF
and death.9e11 These studies have suggested that at higher
doses, regeneration is inhibited because of blockade in critical
proregenerative signaling pathways.9,11,12 On the basis of this
principle, we developed a novel incremental dose model to
delineate the mechanisms of liver regeneration after APAP-
induced acute liver injury (ALI). We used two doses of
APAP, a lower dose (300 mg/kg), after which liver regener-
ation is intact, and a higher dose (600mg/kg), after which liver
regeneration is inhibited. We performed a comprehensive
analysis of several signaling pathways known to be involved
in liver regeneration and identiﬁed pathways that are poten-
tially important for liver regeneration after APAP-induced
ALI; these pathways can be targeted therapeutically.
Materials and Methods
Animals, Treatment, and Tissue Harvesting
Two-month-old male C57BL/6 mice, purchased from
Jackson Laboratories (Bar Harbor, ME), were used in these
studies. Mice overexpressing a stable form of b-catenin,
where serine 45 is mutated to aspartic acid (S45D), have been
described before.13 Details of generation and characterization
of these mice have been published previously.13 All animals
were housed in Association for Assessment and Accredita-
tion of Laboratory Animal Careeaccredited facilities at the
University of Kansas Medical Center (Kansas City, KS)
under a standard 12-hour light/dark cycle with access to chow
and water ad libitum. The Institutional Animal Care and Use
Committee at University of Kansas Medical Center approved
all studies. Mice were fasted 12 hours before administration
of APAP. APAP was dissolved in warm 0.9% saline, and
mice were treated with either 300 or 600 mg/kg APAP, i.p.
Food was returned to the mice after APAP treatment. Mice
(nZ 3 to 7) were sacriﬁced at 0, 0.5, 1, 3, 6, 12, 24, 48, 72,
and 96 hours after APAP treatment by cervical dislocation
under isoﬂurane anesthesia, and blood and livers were
collected. The S45D and respective wild-type (WT) litter-
mates were treated with either 300 or 600 mg/kg APAP and
sacriﬁced at 6 and 24 hours (APAP300 study) or 24 and 48
hours (APAP600 study) after APAP administration, followed
by blood and liver collection. Serum samples were obtained
from the blood and used for analysis of alanine aminotrans-
ferase (ALT) activity using commercially available kits
(ThermoFisher Scientiﬁc, Pittsburgh, PA). Liver sections and3014nuclear and cytoplasmic protein extracts were prepared as
described previously.14
Antibodies
All primary antibodies obtained from Cell Signaling
Technologies (Danvers, MA) for Western blot analysis
and their catalog numbers are provided in Table 1. Active
b-catenin antibody was obtained from EMD Millipore
Corporation (Billerica, MA) (catalog number 05-665). All
secondary antibodies used for Western blot analysis were
obtained from Cell Signaling Technologies. Biotinylated
secondary antibodies for immunohistochemistry (IHC)
were purchased from Jackson Immunoresearch (West
Grove, PA).
Protein Isolation and Western Blot Analysis
Protein estimation and Western blot analysis were per-
formed using pooled samples of protein extracts prepared
from frozen liver tissues, as previously published, without
any modiﬁcations.14
PCNA IHC
Parafﬁn-embedded liver sections (4 mm thick) were used for
IHC detection of proliferating cell nuclear antigen (PCNA),
as described before.14
Real-Time PCR
Total RNAwas isolated fromAPAP300 and APAP600 livers
using the TRIzol method, according to the manufacturer’s
protocol (Sigma, St. Louis, MO), and converted to cDNA, as
previously described.5 mRNA levels of various genes were
determined using real-time PCR analysis using commercially
available TaqMan Gene Expression Assays (Life Technolo-
gies, previously known as Applied Biosystems, Carlsbad,
CA) on the Applied Biosystems Prism 7300 Real-Time PCR
Instrument, according to the manufacturer’s protocol. Rplp0
gene expression in the same samples was used for data
normalization, and data were expressed as fold change
compared with 0 hour.
ChIP Data
Chromatin immunoprecipitation (ChIP) was done using whole
liver tissue from APAP300 and APAP600 animals for the
12-hour time point, as described previously.15 Chromatin was
isolated using approximately 200mg of frozen liver tissue from
three mice of each group. Isolated chromatin was then incu-
bated with no antibody, 5 mg b-catenin (catalog number
610154; BD Transduction, Danvers, MA) or 5 mg p65 (catalog
number 8242; Cell Signaling Technologies) antibodies for
immunoprecipitation. Real-time PCR analysis was done using
primers designed to cover known p65 and b-catenin binding
sites on Ccnd1 promoter. Data were normalized with inputajp.amjpathol.org - The American Journal of Pathology
Table 1 Antibodies Used in This Study and Their Catalog
Numbers
Antibody Catalog no.*
Cyclin D1 2978
CDK4 2906
Phospho-Rb (Ser807/811) 9308
PCNA 2586
p21 2947
p27 3688
b-Catenin 8480
Phospho-b-catenin (Ser45/Thr41) 9565
Phospho-b-catenin (Ser33/37/Thr41) 9561
GSK-3b 9315
Phospho-GSK-3b (Ser9) 9323
Dvl2 3224
JNK 1 3708
Phospho-JNK (Thr183/Tyr185) 4668
c-Jun 9165
c-Fos 2250
STAT-3 4904
PhosphoeSTAT-3 9145
EGFR 4267
Phospho-EGFR (Tyr1068) 3777
AKT 4691
Phospho-AKT 9271
p38 9212
Phospho-p38 9211
ERK1/2 9102
Phospho-EKR1/2 4376
c-Met 4560
Phospho-Met (Tyr1234/1235) 3077
p65 8242
Phospho-p65 (Ser536) 3033
IkB 4812
GAPDH 2118
Actin 4970
*Antibodies were obtained from Cell Signaling Technologies (Danvers, MA).
GAPDH, glyceraldehye-3-phosphate dehydrogenase.
Liver Regeneration after APAP OverdoseDNA and represented as fold enrichment with respect to no
antibody control. Primer sequences were as follows: forward,
50-GCAGGACTTTGCAACTTCAAC-30 and reverse, 50-
TTTCTCTGCCCGGCTTTG-30.
Statistical Analysis
Data presented in the form of bar/line graphs show
means  SEM. A signiﬁcant difference between groups was
determined using Student’s t-test. A difference between
groups was considered statistically signiﬁcant at P < 0.05.
Results
Sustained Injury and Inhibited Recovery after Higher
Dose of APAP
We compared liver injury at the two doses of APAP
(APAP300 and APAP600) over the time course of 0 to 96The American Journal of Pathology - ajp.amjpathol.orghours by studying serum ALT and histopathological analysis
of liver sections (scoring sections for percentage necrosis)
(Figure 1, AeC). Liver injury increased after APAP treatment
and peaked at 12 hours after treatment at both doses. Liver
injury was characterized by necrosis in the centrilobular re-
gion, a hallmark of APAP toxicity. Interestingly, there was no
signiﬁcant difference in injury up to 24 hours in both the
groups, except area of necrosis was signiﬁcantly higher at 12
hours in APAP600 compared with APAP300 group
(Figure 1C). The overall trend showed moderately higher
injury in APAP600 group up to 24 hours. However, there was
a marked difference in progression of injury at later time
points. APAP300 showed slight regression of injury at 48
hours and complete recovery at 72 and 96 hours, as evidenced
by decreased serum ALT levels, complete recovery from ne-
crosis, and 100% survival. In contrast, approximately 25%
animals died at various time points from 48 to 96 hours in the
APAP600 group (Figure 1B). Remaining animals showed
sustained injury and were not recovered up to 96 hours. Injury
was strikingly higher at 72 and 96 hours in the APAP600
group compared with the APAP300 group. In addition, we
investigated other parameters of liver failure (serum glucose
and bilirubin levels) in APAP300 and APAP600 mice, which
displayed a similar pattern showing a signiﬁcant difference
between the two groups at later time points of 48 to 96 hours
after APAP treatment (Supplemental Figure S1, A and B).
Inhibited Liver Regeneration and Cell Cycle Arrest
Correlate with Sustained Injury and Inhibited Recovery
at a Higher Dose
Next, we studied liver regeneration at the two doses of APAP
using PCNA IHC (Figure 2A). Quantiﬁcation of total PCNA-
positive cells (Figure 2B) showed evidence of a few cells
entering the cell cycle as early as 3 hours in APAP300, but a
robust proliferation response with a dramatic increase in
PCNA-positive cells was observed only from 12 hours after
APAP treatment, speciﬁcally around necrotic areas. PCNA-
positive cells remain elevated up to 48 hours and then pro-
gressively decreased at 72 and 96 hours. In contrast, APAP600
showed almost no PCNA-positive cells up to 24 hours after
APAP administration. PCNA-positive cells started appearing
at a much delayed time point of 48 hours onward in the
APAP600 group and were signiﬁcantly lower compared with
peak cell proliferation observed in the APAP300 group. The
PCNA data were corroborated by Ki-67 immunoﬂuorescence
staining (Supplemental Figure S2). Overall, there was signif-
icantly delayed and attenuated liver regeneration in the
APAP600 group, which correlated with sustained injury,
delayed recovery, and decreased survival at a higher dose.
Interestingly, even at the time point of peak injury (12
hours after APAP treatment) at a higher dose, >50% of
hepatocytes were still intact, as demonstrated by necrosis
scoring. This suggests that a marked decrease in regenera-
tion in the APAP600 dose is not due to lack of viable
hepatocyte in the higher dose. This was further conﬁrmed3015
Figure 1 Sustained liver injury and inhibited
recovery after higher dose of APAP. A: Represen-
tative photomicrographs of H&E-stained liver
sections with necrotic area outlined. B: Bar graph
shows serum ALT levels with percentage survival
speciﬁed over bars at time points where any
mortality was observed. C: Bar graph shows per-
centage necrosis area on the basis of H&E-stained
liver sections. All samples were collected from
mice treated with either APAP300 or APAP600 at
various time points up to 96 hours after APAP
treatment. *P < 0.05 between two doses. CV,
central vein; PT, portal triad.
Bhushan et alby hepatocyte nuclear factor (HNF) 4a staining as a marker
of intact hepatocytes (Supplemental Figure S3). In fact,
overall cellular death was not strikingly different at the two
doses at early time points, where regeneration was initiated
at a lower dose. Furthermore, a closer look at individual
animal data revealed that, although there was no difference
in liver injury in some animals between groups, there was a
striking difference in regenerative response (data not
shown).
Next, we quantiﬁed cells in a speciﬁc cell cycle phase by
studying PCNA-stained sections in detail to further look
into progression of cell cycle (Figure 2, CeF). In the
APAP300 group, cells started entering the cell cycle at 12
hours, with numerous cells entering into the G1 phase from
the G0 phase. At 24 hours, most of the cells were still in the
G1 phase, with many cells progressed to the S phase. Most
of the cells progressed to the S phase at 48 hours and further
to the G2 phase by 72 hours. Mitoses were evident between
48 and 96 hours. By 96 hours, most cells returned to the
quiescent state. In contrast, in the APAP600 group, almost
all of the cells stayed in the G0 phase up to 24 hours. A few
cells started entering the G1 phase only at a much delayed
time point of 48 hours, and furthermore, these cells do not
progress through the cell cycle at later time points and
remain arrested at the G1 phase. No mitotic activity was
observed at any time points in the APAP600 group. These
results suggest that inhibition of entry into cell cycle and
early cell cycle arrest in the remaining viable hepatocytes at3016higher dose are the reason for inhibited liver regeneration,
rather than mere higher cell death.
Cell Cycle Regulators Correlate with Arrested Cell Cycle
and Inhibited Liver Regeneration at a Higher Dose
We further studied expression of various core cell cycle pro-
teins, which regulate cell cycle entry. We ﬁrst determined
cyclin D1 levels, induction of which is the critical step that is
required by hepatocytes for progressing through the G1 phase
and committing to DNA replication.16 There was an early
twofold induction of cyclin D1mRNA at 3 hours, followed by
a sharp peak (sixfold induction) at 12 hours, speciﬁcally in the
APAP300 group, correlating with time of onset of the regen-
erative phase. Cyclin D1 mRNA level rapidly declined at 24
hours to approximately 2.5-fold and reached to basal level by
96 hours. In contrast, cyclin D1 mRNA did not increase
signiﬁcantly in the APAP600 group at any time point but
showed slight induction in some animals at much delayed time
points of 48 and 96 hours (Figure 3A). Moreover, we observed
a signiﬁcant decrease in cyclin D1 mRNA levels at 6 hours
compared with basal levels in the APAP600 group, suggesting
active inhibition of the cell cycle.Western blot analysis further
corroborated mRNA data with an early and overall much
higher increase in cyclin D1 protein only in APAP300 dose,
correlating with PCNA protein expression (Figure 3B). Cyclin
D1 binds to cyclin-dependent kinase (CDK) 4, and this com-
plex, in turn, causes phosphorylation and inactivation ofajp.amjpathol.org - The American Journal of Pathology
Figure 2 Inhibition of liver regeneration
following higher doses of APAP. A: Representative
photomicrographs of PCNA-stained liver sections.
Insets: Cells in speciﬁc phase of cell cycle (ar-
rows), indicating different phases of the cell
cycle. G0, G1, and S cells show blue, light brown,
and deep brown nuclear staining, respectively; G2
cells, diffused brown cytoplasmic staining; and M
phase cells, deep blue chromosomal staining. B:
Line graph shows total number of PCNA-positive
cells per ﬁve high-power (40) ﬁelds. CeF: Line
graphs show total number of cells in G1 (C), S (D),
G2 (E), and M (F) phases per ﬁve high-power
(40) ﬁelds, demonstrating cell cycle progres-
sion. All samples were collected from mice treated
with either APAP300 or APAP600 over a time
course of 0 to 96 hours after APAP treatment.
*P < 0.05 between two doses. CV, central vein;
PT, portal triad.
Liver Regeneration after APAP Overdoseretinoblastoma (Rb), which ultimately leads to transcription of
many cell cycle genes.16 CDK4 protein and phosphorylation
of Rb followed a trend similar to cyclin D1 expression
(Figure 3B).
We further analyzed the dynamics of CDK inhibitors, p21
and p27, to elucidate if active cell cycle inhibition is
involved at a higher dose (Figure 3, C and D). Interestingly,
p21 mRNA was markedly induced at both the doses as early
as 3 hours after APAP. However, induction was much
higher and sustained up to 96 hours at a higher dose but
decreased remarkably after 24 hours at a lower dose
(Figure 3C). Protein expression of p21 also displayed a
similar trend. The p27 protein also showed moderate
induction at both doses, showing a pattern similar to p21,
with notable higher expression at 6 hours after APAP
treatment at higher dose, the time point preceding onset of
normal liver regeneration response in regenerative dose
(Figure 3D). These data suggest that active cell cycle
inhibition is involved at a higher dose of APAP, where liver
regeneration is inhibited.The American Journal of Pathology - ajp.amjpathol.orgOverall, early and robust induction of cyclin D1 at a
lower dose resulted in timely liver regeneration and recov-
ery. Inhibition of such a robust and timely response and
sustained activation of cell cycle inhibitors at a higher dose
correlated with cell cycle arrest, inhibited liver regeneration,
progression of injury, and decreased survival. Next, we
studied major upstream pathways, which are known to
induce cyclin D1 and stimulate liver regeneration. For these
studies, on the basis of the time course of regenerative
response, we focused on time points up to 24 hours after
APAP treatment, considering the importance of early
regenerative response for successful recovery.
Growth Factor Signaling via EGFR and c-Met and MAPK
Signaling Remain Highly Activated after High Dose of
APAP
Epidermal growth factor (EGF) and hepatocyte growth factor
(HGF) are considered the primary mitogens for hepatocytes
and are critical for liver regeneration after PHX.8 EGF and3017
Figure 3 Cell cycle regulators correlate with
inhibited liver regeneration at higher dose. Cyclin D1
(A) and p21 (C) mRNA expression, cyclin D1, CDK4,
phospho-Rb, and PCNA (B) and p21 and p27 (D)
protein expression in liver of mice treated with
either APAP300 or APAP600. All samples were
collected over a time course of 0 to 96 hours after
APAP treatment. *P < 0.05 between two doses.
GAPDH, glyceraldehye-3-phosphate dehydrogenase.
Bhushan et alHGF act primarily through activation of EGF receptor (EGFR)
and c-Met receptor, respectively.8 This leads to, among others,
activation of mitogen-activated protein kinase (MAPK)
signaling, culminating in cell proliferation. However, the
importance of these growth factors in liver regeneration after
APAP-induced ALI is not known. We found that the protein
expression of EGFR and c-Met was increased at both the doses
(Figure 4A). To determine activation status of these receptors,
we investigated the expression of phosphorylated forms of
EGFR and c-Met. There was remarkable activation of EGFR
as early as 0.5 hours after APAP300 treatment, attaining a peak
at 6 hours, the time point preceding onset of marked liver
regeneration response, and then progressively decreased at
later time points. Interestingly, a similar trendwas observed for
the APAP600 group, withmuch higher and sustained response
in a dose-dependent manner (Figure 4A). Similar results were
observed for c-Met activation, for which we found marked
phosphorylation only at 6 hours after APAP300 treatment, but
much higher and sustained phosphorylation after APAP600
treatment, starting as early as 3 hours and maintained until
12 hours (Figure 4A). Further studies on downstream
MAPK signaling revealed that AKT, p38, extracellular
signaleregulated kinase (ERK) 1/2, and c-Jun N-terminal
kinase (JNK) total protein levels remained unchanged after
both the doses. However, a dose-dependent increase in
phosphorylation (activation) of all these kinases, including
AKT, p38, ERK1/2, and JNK, was observed after APAP
treatment (Figure 4, B, C, and EeH). Activation of all these
kinases was higher in the APAP600 group compared with
the APAP300 group. Furthermore, a similar trend was
observed for expression of downstream transcription fac-
tors, c-Jun and c-Fos (Figure 4D). Overall, these results
suggest that signaling through growth factor and down-
stream MAPKs remains activated even at the dose of APAP3018where liver regeneration is inhibited. Thus, lack of activa-
tion of these signaling factors may not be the reason for
failed liver regeneration at a higher dose.
Apart from involvement in cell proliferation and liver
regeneration pathways,17 JNK activation is also considered
as one of the important steps in mediating APAP
overdoseeinduced liver injury.18 Phosphorylation of JNK
and its translocation to mitochondria early in APAP toxicity
leads to exacerbation of mitochondrial oxidant stress.18
Despite previous attempts, the role of JNK activation in
liver regeneration after APAP overdose remains undeﬁned
and should be further evaluated.19
Differential Activation of Cytokine Pathways (IL-6/
STAT-3 and TNF-a/NF-kB) during Liver Regeneration
after APAP Overdose
Activation of cytokine pathways [IL-6/STAT-3 and tumor
necrosis factor (TNF)-a/NF-kB] is considered as an important
priming event that contributes to initiation of early stages of
liver regeneration after PHX.16 However, their role in liver
regeneration after APAP overdose is not known. IL-6 mRNA
was induced at both the doses of APAP as early as 3 hours
after APAP treatment and remains induced up to 24 hours,
showing a peak at 12 hours after APAP treatment (Figure 5A).
Interestingly, IL-6 induction was greater at a higher dose of
APAP, at which regeneration was inhibited. IL-6 binding to
its receptor at the cellular membrane leads to phosphorylation
and nuclear translocation of STAT-3, which ultimately results
in transcription of many target genes. Corroborating IL-6
data, we observed signiﬁcantly higher phosphorylation of
STAT-3 in APAP600 mice, which showed less regeneration
(Figure 5B). Although STAT-3 phosphorylation was transient
(appeared at 6 and 12 hours) in the APAP300 group, it startedajp.amjpathol.org - The American Journal of Pathology
Figure 4 Growth factor signaling via EGFR and
c-Met and MAPK signaling remain highly activated
after high dose of APAP. Western blot analysis of
EGFR, phospho-EGFR (normal and high exposures),
c-Met, phospho-Met (A), total AKT, phospho-AKT,
total p38, phospho-p38, total ERK1/2,
phospho-ERK 1/2 (B), total JNK, phospho-JNK
(C), and c-Jun and c-Fos (D) using total liver
extract of mice liver treated with either APAP300
or APAP600. Densitometric analysis shows p38
(E), ERK1/2 (F), JNK (G), and AKT (H) activation.
All samples were collected over a time course of
0 to 24 hours after APAP treatment. GAPDH,
glyceraldehye-3-phosphate dehydrogenase.
Liver Regeneration after APAP Overdoseearly (at 3 hours) and maintained until 24 hours in the
APAP600 group. Although total STAT-3 levels were induced
after APAP treatment in both doses, no signiﬁcant difference
between the groups was observed. Overall, these data suggest
that, similar to growth factor signaling, IL-6 signaling remains
intact, even at a nonregenerative dose of APAP; thus, it may
not explain failed liver regeneration at a higher dose.
Next, we determined the status of NF-kB signaling during
liver regeneration after APAP-induced ALI using our
incremental dosemodel (Figure 5, C andD). TNF-a binding to
its receptor ultimately results in stabilization and nuclear
translocation of transcription factor NF-kB (consisting of p65
as one of its subunits). Cyclin D1 is a known target of NF-
kB.20 Interestingly, TNF-awas induced at early time points (3
and 6 hours), preceding the regenerative phase, speciﬁcally in
a lower (regenerative) dose, and its mRNA level peaked at 12
hours after APAP treatment. In contrast, TNF-a was not
induced until 12 hours after APAP in a higher dose and overall
showed much lower induction compared with APAP300 doseThe American Journal of Pathology - ajp.amjpathol.org(Figure 5C). Furthermore, there was a marked increase in
phosphorylation of p65 at Ser536, known to enhance trans-
activation potential of p65,21 in the APAP300 group preceding
regenerative phase (6 hours after APAP) and sustained until 24
hours (Figure 5D). Although the APAP600 group also showed
an increase in Ser536 phosphorylation, it was only at 12 hours
after APAP andwas overall lower than in the APAP300 group.
Althoughmarked nuclear translocation of p65 was observed at
both the doses, the increase in nuclear p65 was sustained in the
APAP300 group until 24 hours after APAP, but declined
sharply at 12 and 24 hours after APAP in the APAP600 group.
Total p65 protein expression was increased in both the groups
at all of the time points compared with basal levels, and IkB
protein level did not appear to change at any dose (Figure 5D).
Overall, activation of NF-kB signaling correlated with
stimulation of liver regeneration at a lower dose, and we
observed an indication of inhibited activation of NF-kB
signaling at a higher dose, where liver regeneration was
inhibited. Considering cyclin D1 is a known target of p-65, we3019
Figure 5 Differential activation of cytokine pathways during liver regeneration after APAP overdose. IL-6 (A) and TNF-a (C) mRNA expression in liver of mice
treated with either APAP300 or APAP600. Western blot analysis of total STAT-3, phospho STAT-3 (B), total, nuclear, phosphorylated p65, and IkB (D) using total liver
extract (unless speciﬁed) ofmice treatedwith either APAP300 or APAP600. All samples were collected over a time course of 0 to 24 hours after APAP treatment. E: ChIP
analysis shows p65 binding to cyclin D1 promoter at 12 hours after either APAP300 or APAP600 treatment. *P< 0.05 between two doses. GAPDH, glyceraldehye-3-
phosphate dehydrogenase.
Bhushan et alwanted to directly compare p-65 binding with cyclin D1
promoter at the two doses using ChIP assay (Figure 5E).
Interestingly, we observed an approximately 2.5-fold higher
binding of p-65 to cyclin D1 promoter in the APAP300
compared with the APAP600 group, 12 hours after APAP
treatment, which is the time point of peak induction of cyclin
D1. These data suggest that inhibited activation of NF-kB
signaling may be one of the reasons for inhibited cyclin D1
induction and inhibited liver regeneration at a higher dose.
Activation of Wnt/b-Catenin Signaling Is Inhibited
after a Higher Dose of APAP
Previous reports have demonstrated involvement of b-cat-
enin activation in liver regeneration after PHX and APAP-
induced ALI.5,22 Herein, we further analyzed the role ofWnt/
b-catenin signaling in detail using our incremental dose
model. Although total b-catenin protein remained unchanged
in both the groups at all time points, a substantial increase in
nuclear b-catenin was observed at 12 and 24 hours after
APAP overdose in the APAP300 group (Figure 6A). In
contrast, APAP600 exhibited an initial increase in nuclear b-
catenin at 0.5 and 1 hour after APAP treatment, which
decreased at later time points. The decline in nuclear b-cat-
enin was consistent with a substantial increase in two inactive
forms of b-catenin (Ser45/Thr41 phosphorylated and Ser33/
37/Thr41 phosphorylated) in APAP600 mice.
To further study the upstream mechanism, we determined
expression of total and phosphorylated (inactive) forms of
glycogen synthase kinase-3b (GSK3b), which regulates
b-catenin degradation in canonical Wnt signaling (Figure 6B).3020Data indicate signiﬁcant inactivation of GSK3b, as shown by a
marked increase in phospho-GSK3b protein in APAP300
mice between 6 and 24 hours after APAP overdose, correlating
with b-catenin activation. Interestingly, a higher dose showed
initial GSK3b inactivation to some extent (less compared with
APAP 300), but this inactivation markedly decreased during
later phase. The decreased inactivation (or increased activa-
tion) of GSK3b at 6 to 24 hours after APAP treatment in the
APAP600 group is consistent with an increase in phosphory-
lated b-catenin species (inactive). Next, we determined protein
expression ofDvl, which acts upstream ofGSK3b in canonical
Wnt signaling and is activated by Wnt binding to Frizzled
(Fzd) receptor. A signiﬁcant increase in Dvl expression was
observed in the APAP300 group at 12 and 24 hours after
APAP. In contrast, Dvl expression increased early after
APAP600 dose but declined during the regenerative phase
(Supplemental Figure S4).
To determine whether expression of any of the Wnts and
Fzds is induced during APAP-induced liver regeneration,
we quantiﬁed mRNA of all 11 Wnts and 10 Fzld genes
known to be expressed in the liver.23 The data indicate that
Wnt4 (Figure 6C) and Wnt5a (Figure 6D) mRNA exhibited
signiﬁcant induction in the APAP300 group during regen-
erative phase (12 and 24 hours). However, none of the Wnt
mRNAs were induced at any time point after APAP600
dose. Among the Fzd genes, Fzd7 was signiﬁcantly induced
only in the APAP300 group between 3 and 12 hours,
whereas Fzd8 showed an opposite trend, with slight but
signiﬁcant induction in the APAP600 group at 12 and 24
hours (Supplemental Figure S4). All other Fzd genes
remained unaffected in both groups.ajp.amjpathol.org - The American Journal of Pathology
Figure 6 Activation of Wnt/b-catenin signaling is inhibited after a higher dose of APAP. Western blot analysis of total b-catenin, nuclear b-catenin, phospho-b-
catenin (S45/Thr41), phospho-b-catenin (S33/37/Thr41) (A) and total GSK-3b and phospho-GSK-3b (B). Total liver extracts (unless speciﬁed) of mice treated with
either APAP300 or APAP600 were used for Western blot analyses. mRNA expression of Wnt4 (C) and Wnt5a (D) in liver of mice treated with either APAP300 or
APAP600. All samples were collected over a time course of 0 to 24 hours after APAP treatment. E: ChIP analysis shows b-catenin binding to cyclin D1 promoter at 12
hours after either APAP300 or APAP600 treatment. *P < 0.05 between two doses. GAPDH, glyceraldehye-3-phosphate dehydrogenase.
Liver Regeneration after APAP OverdoseOverall, we observed stimulation of Wnt/b-catenin
signaling speciﬁcally in a regenerating dose, correlating
with induction of cyclin D1, which is a known target of
b-catenin.24 Furthermore, activation of Wnt/b-catenin
signaling was inhibited at a higher dose, correlating with
inhibited cyclin D1 induction. Finally, we directly checked
if there is a difference in b-catenin binding to cyclin D1
promoter at the two doses using ChIP assay. We observed
an approximately twofold higher enrichment of b-catenin
binding to cyclin D1 promoter in APAP300 compared with
APAP600 group, 12 hours after APAP treatment, which is
the time point of peak induction of cyclin D1 (Figure 6E).
Taken together, these data suggest that inhibited activation
of Wnt/b-catenin signaling may be one of the reasons for
inhibited cyclin D1 induction and inhibited liver regenera-
tion at a higher dose.
Increased Liver Regeneration in Mice Overexpressing
b-catenin after APAP Overdose
Our studies using the incremental dose model identiﬁedWnt/
b-catenin signaling as a potential target for stimulating liver
regeneration after APAP overdose. We further conﬁrmed the
role of b-catenin in stimulation of liver regeneration after
APAP overdose using mice overexpressing S45D. Pre-
liminary analysis showed moderately higher total b-catenin
in the S45D mice, which is consistent with previous studies
(Supplemental Figure S5A).13 Further analysis indicated no
signiﬁcant difference in hepatic CYP2E1, the main enzyme
involved in APAP bioactivation, in S45D mice compared
with WT mice (Supplemental Figure S5A). Preliminary
studies indicated that the WT control mice for the S45D
strain, which are the S45D negative littermates, are moreThe American Journal of Pathology - ajp.amjpathol.orgsusceptible to APAP than C57BL/6 mice. Therefore, we
initially used a dose of 300 mg/kg APAP in this study, which
was sufﬁcient to show attenuated liver regeneration response
in WT mice. WT and S45D mice were treated with 300 mg/
kg APAP, and liver injury and regeneration were analyzed at
6 and 24 hours after APAP treatment. Serum ALT levels and
necrosis scoring demonstrated similar liver injury in WT and
S45D mice at both the time points after APAP (Figure 7,
AeC), suggesting the injury process is not altered in S45D
mice. Although WT mice showed only a few PCNA-positive
hepatocytes at 24 hours after APAP treatment, liver regen-
eration was remarkably improved in S45D mice, as indicated
by higher PCNA-positive hepatocytes in S45D mice at 24
hours after APAP treatment, compared with WT mice
(Figure 7D). This was further substantiated by PCNA protein
expression, which displayed a similar pattern (Figure 7E).
Western blot analysis indicated signiﬁcantly higher activated
b-catenin in S45D mice at 24 hours after APAP treatment
(Figure 7E). An increase in activated b-catenin was accom-
panied by increased cyclin D1 and phosphorylation of Rb
protein in S45D mice at 24 hours after APAP overdose
(Figure 7E). Real-time PCR analysis indicated increased
gene expression of cyclin D1 and axin 2, the known targets of
b-catenin, in S45D mice after APAP treatment, compared
with WT mice at 24 hours after APAP overdose
(Supplemental Figure S5, B and C). Next, we studied liver
regeneration in S45D mice after a higher dose of APAP (600
mg/kg) (Figure 7, FeJ). Neither WT nor S45D mice showed
any signiﬁcant liver regeneration at 24 hours after APAP.
However, S45D mice showed higher PCNA-positive cells
(with higher PCNA protein expression) compared with WT
mice (Figure 7, F, I, and J) at 48 hours after APAP treatment.
This was further substantiated by higher cyclin D1 protein3021
Bhushan et alexpression and downstream phosphorylation of Rb protein in
S45D mice compared with WT mice at 48 hours after APAP
treatment (Figure 7J). Similar to APAP300 dose, both WT
and S45Dmice showed similar injury at 24 and 48 hours after
APAP600 treatment (Figure 7, FeH). These data show that
overexpression of b-catenin resulted in faster and higher liver
regeneration after APAP overdose.Figure 7 Overexpression of stable form of b-catenin improves liver regenerat
PCNA-stained liver sections from WT and S45D mice treated with 300 mg/kg APAP
and PCNA counts (D) in WT (black bars) and S45D (gray bars) mice treated with
PCNA using total liver extracts in WT and S45D mice treated with APAP300. F: Rep
WT and S45D mice treated with APAP600. Bar graphs show serum ALT levels (G), pe
(gray bars) mice treated with APAP600. J: Western blot analysis of active b-caten
treated with APAP600. *P < 0.05 between WT and S45D group. Arrowhead represe
3022Discussion
APAP overdose is the foremost cause of ALF in the United
States, contributing to approximately 46% of all ALF
cases.25 Treatment options after APAP-induced ALF are
extremely limited. Extensive research on chemicals and
drugs that induce liver injury has shown that compensatoryion after APAP overdose. A: Representative photomicrographs of H&E- and
. BeD: Bar graphs show serum ALT levels (B), percentage necrosis area (C),
APAP300. E: Western blot analysis of active b-catenin, cyclin D1, pRb, and
resentative photomicrographs of H&E- and PCNA-stained liver sections from
rcentage necrosis area (H), and PCNA counts (I) in WT (black bars) and S45D
in, cyclin D1, pRb, and PCNA using total liver extracts in WT and S45D mice
nts PCNA-positive cells. GAPDH, glyceraldehye-3-phosphate dehydrogenase.
ajp.amjpathol.org - The American Journal of Pathology
Liver Regeneration after APAP Overdoseliver regeneration plays a critical role in determination of
ﬁnal outcome of injury. It is known that timely stimulation
of regeneration leads to regression of injury, whereas failing
to regenerate culminates in progression of injury and
death.9,11,26 Several recent clinical and animal studies
showing similar ﬁndings after APAP overdose suggest that
stimulating liver regeneration can be a potential treatment
option for APAP-induced ALF.5e7 However, our knowl-
edge regarding mechanisms of liver regeneration after
APAP-induced injury is extremely limited, and there is a
critical need to study these mechanisms systematically.
Dynamics of liver regeneration after toxic insult have
been extensively studied for many toxicants, such as thio-
acetamide,11 carbon tertrachloride,27 and chloroform.26
These studies demonstrated that liver regeneration follows
classic rules of dose-response such that regeneration in-
creases with dose of toxicant proportionate to injury. This
occurs until a threshold dose beyond which the ability of
liver to regenerate declines, leading to progression of
injury.9 On the basis of this principle, we developed an
incremental dose model to study mechanisms of liver
regeneration after APAP-induced ALI.
Herein, we used two doses of APAP, a lower dose (300
mg/kg) that caused extensive liver injury but also signiﬁcant
compensatory regeneration, leading to regression of injury
and spontaneous recovery, and a higher dose (600 mg/kg)
that caused sustained injury, compromised recovery, and
decreased survival. We observed marked inhibition of liver
regeneration at a higher dose, highlighting the importance of
liver regeneration in overall survival after APAP overdose,
supporting previous ﬁndings.5e7 The marked inhibition of
regeneration was not due to lack of viable hepatocytes at the
higher dose. Necrosis score analysis and IHC staining for
HNF4a, which stains for viable hepatocytes, demonstrated
that >50% hepatocytes were viable in APAP600 dose at
peak injury. In fact, overall cellular death was not strikingly
different at the two doses at early time points, where
regeneration was initiated at lower dose and inhibited at
higher dose. These data and further analysis of cell cycle
phases indicated that the inhibition of regeneration was not
simply because of too much cell death but due to inhibited
cell cycle entry and cell cycle arrest at an early stage in
viable cells surrounding the necrotic zone at a higher dose.
Higher cellular stress in viable hepatocytes may be a
possible explanation for this inhibited liver regeneration at a
higher dose. This observation also distinguishes the APAP
incremental dose model from 90% PHX model, in which the
primary reason behind decreased liver regeneration is lack
of critical mass required to initiate regeneration.
Our most remarkable ﬁnding was that cyclin D1 mRNA
and protein expression increased in the lower dose preced-
ing the start of regenerative phase, but this was completely
inhibited in the higher dose. These data further support that
initial entry into the cell cycle is inhibited at a higher dose,
underlining the importance of induction of cyclin D1 in
regulation of liver regeneration after APAP-induced ALI.The American Journal of Pathology - ajp.amjpathol.orgFurthermore, we found higher and sustained induction of
p21 protein at a higher dose, supporting possible contribu-
tion of active inhibition of cell cycle in cell cycle arrest at
higher dose due to elevated cellular stress. Similar results
were reported previously after ethanol treatment in the
PHX model, where ethanol inhibited cyclin D1, induced p21,
and impaired liver regeneration.28 Interestingly, there was
moderate induction of p21, even at the regenerative dose,
suggesting possible role of p21 in coordinating liver regen-
eration. Recent study demonstrating role reversal of p21 in
liver regeneration, depending on degree of injury, certainly
supports this possibility.29 Further studies are required to
determine the exact role of p21 in liver regeneration after
APAP overdose.
Several regenerative pathways, such as growth factors/
MAPKs, TNF-a/NF-kB, Wnt/b-catenin, and IL-6/STAT-3,
are known to induce cyclin D1 and hepatocyte prolifera-
tion.8 We determined the status of some of these pathways
in our model to look further into the mechanism behind
differential expression of cyclin D1 at both the doses. There
was remarkable activation of growth factor receptors (c-Met
and EGFR), downstream MAPKs (ERK1/2, p38, and JNK),
and IL-6/STAT-3 signaling at the regenerative dose, but,
interestingly, activation was much higher and sustained at
the nonregenerative dose. Previous studies suggest that
some of these pathways may be important for normal liver
regeneration after APAP overdose, where animals sponta-
neously regenerate. For instance, liver regeneration was
found to be impaired in IL-6 knockout mice after moderate
APAP overdose.30 Further conﬁrmatory studies are required
to demonstrate the role of some of these pathways in liver
regeneration after APAP overdose.
However, our data clearly indicate, for the ﬁrst time to
our knowledge, that inability to activate these signaling
pathways is not limiting regeneration at a higher dose,
where animals are not able to recover spontaneously,
because these pathways are already highly activated at this
dose. Additional stimulation of these pathways may not be a
good strategy from a therapeutic standpoint. This also
questions administration of growth factors as a therapeutic
strategy after APAP-induced ALF. This observation is
consistent with previous reports that administration of
growth factors did not affect liver regeneration in dogs after
APAP-induced ALF.31 Also, patients who died after APAP-
induced ALF were found to have a higher amount of HGF
circulating in plasma.32
These data produce two possibilities. First, an active
inhibitory signaling is blocking liver regeneration at a
higher dose, counteracting this regenerative signaling.
Activation of cell cycle inhibitors (eg, p21) is one such
signaling pathway that we observed in this study. Moreover,
some of the known regenerative pathways, which are highly
activated in APAP600, may be actively involved in inhib-
iting regeneration. For instance, overactivation of p38 has
been associated with decreased regeneration in the PHX
model.28,33 Also, p38 can directly inhibit cyclin D13023
Bhushan et alexpression.34 Similarly, impaired regeneration after PHX in
ob/ob mice with fatty liver or in mice with hyper-stimulated
IL-6 signaling was correlated with sustained activation and
overactivation of STAT-3.35,36 Furthermore, sustained
activation of these mediators was correlated with induction
of p21 and inhibition of cyclin D1, which is consistent with
our data.
The second possibility is that speciﬁc critical pathways apart
from the growth factoremediated proregenerative signaling
regulate liver regeneration after APAP overdose. Previous
studies have shown that the Wnt/b-catenin pathway plays a
critical role in liver regeneration, in general, and after APAP
overdose, in particular.5,22 Consistent with these data, we
observed activation of canonical Wnt signaling at the regen-
erative dose. More interestingly, b-catenin activation was
inhibited at a higher dose, where liver regeneration was
inhibited. We also observed TNF-a/NF-kB signaling activa-
tion at the regenerative dose, supporting previous studies
showing a role of TNF receptor in liver regeneration after
APAP overdose.37,38 Furthermore, previous data showed
increased NF-kB DNA binding after APAP treatment, which
was correlated positively with regeneration in mice.39,40
Interestingly, similar to b-catenin signaling, our results indi-
cated that activation of TNF-a/NF-kB signaling is inhibited at
a higher dose, where recovery is compromised. Both b-catenin
and NF-kB are known to transcriptionally regulate and induce
cyclin D1 directly.20,24 Our ChIP data support the important
role of such regulation in liver regeneration after APAP
overdose. Our ﬁndings implicate that inhibited activation of
Wnt/b-catenin and TNF-a/NF-kB signaling may be a
contributing factor to inhibited liver regeneration after severe
APAP overdose and, thus, could be a potential target for
stimulating liver regeneration therapeutically.
Overactivation of b-catenin is known to accelerate liver
regeneration after PHX.13,22 Furthermore, our previous study
showed correlation of b-catenin activation with higher spon-
taneous liver regeneration and survival in patients with APAP-
induced ALF.5 Herein, we observed that mice overexpressing a
mutated form of b-catenin have better liver regeneration after
low and high doses of APAP. Our data, for the ﬁrst time to our
knowledge, indicated that stimulating canonical Wnt signaling
could be a viable approach for improving liver regeneration in
patients with APAP-induced ALF.
In summary, our ﬁndings using a novel comparative
model have demonstrated that high doses of APAP will
inhibit liver regeneration because of active inhibition of cell
cycle progression and/or by lack of stimulation via critical
promitogenic pathways. Some interesting potential pathways
that may be involved in active inhibition of liver regenera-
tion include p38 MAPK and IL-6 signaling and require
further detailed investigation. Furthermore, this study has
revealed canonical Wnt signaling and NF-kB signaling as
potential therapeutic targets to stimulate liver regeneration
after APAP overdose. Finally, our studies indicate that
concomitant inhibition of several inhibitory pathways and
activation of various stimulatory pathways may have a3024promising future in developing regenerative therapies for
APAP-induced patients with ALF.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2014.07.019.
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